全文获取类型
收费全文 | 6333篇 |
免费 | 436篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 193篇 |
妇产科学 | 179篇 |
基础医学 | 806篇 |
口腔科学 | 423篇 |
临床医学 | 488篇 |
内科学 | 1349篇 |
皮肤病学 | 160篇 |
神经病学 | 655篇 |
特种医学 | 122篇 |
外科学 | 783篇 |
综合类 | 34篇 |
一般理论 | 2篇 |
预防医学 | 668篇 |
眼科学 | 66篇 |
药学 | 464篇 |
中国医学 | 19篇 |
肿瘤学 | 310篇 |
出版年
2023年 | 54篇 |
2022年 | 115篇 |
2021年 | 236篇 |
2020年 | 138篇 |
2019年 | 216篇 |
2018年 | 248篇 |
2017年 | 156篇 |
2016年 | 177篇 |
2015年 | 187篇 |
2014年 | 251篇 |
2013年 | 342篇 |
2012年 | 500篇 |
2011年 | 486篇 |
2010年 | 254篇 |
2009年 | 200篇 |
2008年 | 346篇 |
2007年 | 368篇 |
2006年 | 320篇 |
2005年 | 333篇 |
2004年 | 242篇 |
2003年 | 226篇 |
2002年 | 237篇 |
2001年 | 142篇 |
2000年 | 126篇 |
1999年 | 94篇 |
1998年 | 34篇 |
1997年 | 37篇 |
1996年 | 34篇 |
1995年 | 29篇 |
1994年 | 21篇 |
1993年 | 13篇 |
1992年 | 64篇 |
1991年 | 70篇 |
1990年 | 61篇 |
1989年 | 39篇 |
1988年 | 37篇 |
1987年 | 38篇 |
1986年 | 31篇 |
1985年 | 35篇 |
1984年 | 26篇 |
1983年 | 38篇 |
1982年 | 20篇 |
1981年 | 14篇 |
1979年 | 14篇 |
1978年 | 13篇 |
1977年 | 11篇 |
1976年 | 11篇 |
1974年 | 12篇 |
1972年 | 12篇 |
1970年 | 14篇 |
排序方式: 共有6798条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
5.
6.
7.
Modena Débora Aparecida Oliveira Miranda Ana Carolina Godoy Grecco Clovis Liebano Richard Eloin Cordeiro Raquel Cristina Tancsik Guidi Renata Michelini 《Lasers in medical science》2020,35(4):797-806
Lasers in Medical Science - Using light sources in phototherapy has presented promising results regarding several types of facial and body skin affections for centuries. The neodymium-doped yttrium... 相似文献
8.
From early childhood, two brothers had mild gait difficulties due to acid maltase deficiency (AMD). Biochemical studies of family members were consistent with autosomal recessive inheritance, but the asymptomatic mother had AM activity in the homozygote range, and her parents had decreased AM activity. The asymptomatic mother may be homozygous for the adult-onset variant of AMD. Alternatively, either the mother or the children may be genetic compounds of the childhood and adult forms of AMD. 相似文献
9.
S J Graafsma L J van Tits P van Heijst J Reyenga J F Rodrigues de Miranda T Thien 《Journal of cardiovascular pharmacology》1989,14(4):598-602
The effect of handgrip (HG) isometric exercise on plasma catecholamines, alpha 2-adrenoceptors on platelets and beta 2-adrenoceptors on lymphocytes was studied in normotensive subjects (NT) and essential hypertensive subjects (HT). Whereas systolic blood pressure (SBP) increases were similar in NT and HT subjects, diastolic blood pressure (DBP) and heart rate (HR) increased more in the former group. Baseline values and changes in plasma epinephrine (E) and norepinephrine (NE) did not differ between both groups. No differences were apparent in alpha 2-adrenoceptor density and affinity between NT and HT subjects before or after the test. HG isometric exercise induced a similar increase in beta 2-adrenoceptors on lymphocytes of 22 +/- 7 and 13 +/- 5% in NT and HT subjects, respectively. Affinity to the beta 2-adrenoceptors under baseline conditions was somewhat lower in HT (8.1 +/- 0.4 pM) than in NT subjects (6.5 +/- 0.5 pM), and this difference persisted during the test. Our results indicate that there are no differences in alpha 2- and beta 2-adrenoceptor densities either at baseline conditions or after HG isometric exercise between NT and HT subjects. Small differences noted in affinity to the beta 2-adrenoceptors require further investigation. 相似文献
10.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献